HH-160

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameHH-160
Drug Alias NameHH160
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-CTLA4Vascular endothelial growth factor A inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4Vascular endothelial growth factor A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesHuahui Health Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeigene Guangzhou Biologics Manufacturing Co LtdHuahui Health Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A